ConductScience.org, home

Paper476706

Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).

Jayaram HN and 4 others. Cancer Treat Rep, 1979. Cited by 65 papers, by iCite.

Cite this record

ConductScience Library. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA). Papers, record 476706. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/476706

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
65
iCite
Relative citation ratio, by iCite
2.48
iCite
Revised in PubMed
2013-11-21
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jayaram HNH N
2Cooney DAD A
3Vistica DTD T
4Kariya SS
5Johnson RKR K

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Aspartic AcidMajor topic
Neoplasms, ExperimentalMajor topic
Organophosphorus CompoundsMajor topic
Phosphonoacetic AcidMajor topic
Animals
Aspartate Carbamoyltransferase
Biological Transport
Drug Resistance
Female
Kinetics
Male
Mice
Neoplasm Transplantation
Transplantation, Homologous

Source PubMed

Download CSV of topics

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.

PMIDTitleJournalYearIn PapersSource
41886248Repurposing of Inhibitors of Plasmodial Aspartate Transcarbamoylase Toward Trypanosoma Cruzi.ChemMedChem2026https://conductscience.org/library/papers/41886248PubMed
35893264Role of pH in Regulating Cancer Pyrimidine Synthesis.J Xenobiot2022https://conductscience.org/library/papers/35893264PubMed
17336518Design, synthesis, and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase.Bioorg Med Chem Lett2007https://conductscience.org/library/papers/17336518PubMed
7127661A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7127661PubMed
3815730Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3815730PubMed
3581416Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3581416PubMed
1911182Nucleoside salvage and resistance to antimetabolite anticancer agents.Br J Cancer1991https://conductscience.org/library/papers/1911182PubMed
393427m-AMSA and PALA: two new agents in cancer chemotherapy.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/393427PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/476706

GET https://conductscience.org/api/papers/v1/476706/authors